Value Health Sols. Inc. v. Pharm. Research Assocs.

2020 NCBC 41
CourtNorth Carolina Business Court
DecidedMay 22, 2020
Docket18-CVS-12318
StatusPublished
Cited by1 cases

This text of 2020 NCBC 41 (Value Health Sols. Inc. v. Pharm. Research Assocs.) is published on Counsel Stack Legal Research, covering North Carolina Business Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Value Health Sols. Inc. v. Pharm. Research Assocs., 2020 NCBC 41 (N.C. Super. Ct. 2020).

Opinion

Value Health Sols., Inc. v. Pharm. Research Assocs., 2020 NCBC 41.

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE SUPERIOR COURT DIVISION COUNTY OF WAKE 18-CV-12318

VALUE HEALTH SOLUTIONS INC. and NAGARAJAN PARTHASARATHY,

Plaintiffs,

v. ORDER AND OPINION ON DEFENDANTS’ MOTION TO DISMISS AMENDED COMPLAINT PHARMACEUTICAL RESEARCH ASSOCIATES, INC. and PRA HEALTH SCIENCES, INC.,

Defendants.

THIS MATTER comes before the Court on Defendants Pharmaceutical

Research Associates, Inc. (“PRA, Inc.”) and PRA Health Sciences, Inc.’s (“PRA

Health”; collectively Defendants will be referred to herein as “PRA,” in the singular,

except as otherwise required) Motion to Dismiss Plaintiffs’ Amended Complaint.

(“Motion,” ECF No. 77.)

THE COURT, having considered the Motion, the briefs submitted in support

of and in opposition to the Motion, the arguments of counsel at the hearing on the

Motion, the applicable law, and other appropriate matters of record, CONCLUDES

that the Motion should be GRANTED, in part, and DENIED, in part, for the reasons

set forth below.

Mainsail Lawyers, by David Glen Guidry and Joseph Kellam Warren, for Plaintiffs Value Health Solutions Inc. and Nagarajan Parthasarathy. Kilpatrick Townsend & Stockton LLP, by Randy Avram, John Moye, and Joe P. Reynolds, for Defendants Pharmaceutical Research Associates, Inc. and PRA Health Sciences, Inc.

McGuire, Judge.

I. FACTUAL AND PROCEDURAL BACKGROUND

1. The Court does not make findings of fact on motions to dismiss under

Rule 12(b)(6), but only recites those facts included in the complaint that are relevant

to the Court’s determination of the Motion. See, e.g., Concrete Serv. Corp. v. Inv’rs

Grp., Inc., 79 N.C. App. 678, 681, 340 S.E.2d 755, 758 (1986). The facts relevant to

the determination of the Motion are drawn from the Amended Complaint. (“Amended

Complaint,” ECF No. 60.1.)

2. PRA is a “‘contract research organization’ or CRO, in the business of

providing product development and data solution services primarily to drug

companies.” (ECF No. 60.1, at ¶ 1.) PRA conducts clinical trials for pharmaceutical

and biotech companies.

3. Plaintiff Value Health Solutions Inc. (“VHS”) is a developer of clinical

trial management software that CROs use to manage clinical trials. Plaintiff

Nagarajan Parthasarathy (“Parthasarathy”; collectively VHS and Parthasarathy are

“Plaintiffs”) is the founder of VHS. VHS developed a set of clinical trial management

software solutions called ClinTrial Max, Cloud Max, and Info Max (collectively, the

“Software Solutions”). The Software Solutions were cloud-based programs designed

to help drug companies (or CROs on behalf of drug companies) more efficiently

manage the clinical trial process used to develop new drugs. (Id. at ¶ 18.) 4. In April 2014, PRA contacted Parthasarathy to express interest in

acquiring the Software Solutions. In response, Parthasarathy and VHS provided a

day-long demonstration of the software to PRA’s IT leadership team consisting of

Chuck Piccirillo (“Piccirillo”), a senior VP in development, and Mike Irene, a PRA

manager with extensive experience with clinical trial software. (Id. at ¶ 22.)

Plaintiffs and PRA then engaged in a year-long period of due diligence and

negotiation aimed at PRA’s acquisition of the Software Solutions. (Id. at ¶ 24.) VHS

discussed licensing the Software Solutions to PRA in exchange for a recurring license

payment, rather than selling the Software Solutions for a lump sum amount. (Id. at

¶ 26.) However, Plaintiffs allege on information and belief that PRA was not

interested in licensing the Software Solutions from VHS because: (1) PRA wished to

eliminate VHS as a competitor in the marketplace; and (2) prevent VHS from directly

licensing the Software Solutions to drug companies or other CROs. (Id. at ¶ 27.)

5. Between April and October 2014, as part of the due diligence process,

VHS provided PRA with full access to the software code and PRA performed testing

and analysis to understand the functionality of VHS’s Software Solutions from both

a technology and business operations perspective. (Id. at ¶¶ 28–29.) This included a

gap analysis by which PRA learned the capabilities of the Software Solutions and

identified the functions that PRA wanted to further develop after acquiring the

software. (Id.)

6. On October 15, 2014, PRA Health’s Executive Vice President and Chief

Financial Officer, Linda Baddour, sent Parthasarathy a Letter of Intent (“LOI”). (ECF No. 5, at Ex. A.) 1 The LOI outlined PRA’s proposal for the acquisition of the

Software Solutions as follows:

a. A one-time, up-front payment between $1 million and $3 million;

b. Future fixed payments of $333,000 each upon completion of three separate “Integration Milestones,” described as (i) “Integrated Salesforce Environments,” (ii) “Key Product Enhancements,” and (iii) “CTMS Studies Migrated to ClinTrial Max”; and

c. Future variable payments associated with “Performance Milestones” associated with “licenses for VHS” Software Solutions as follows:

i. a payment of $2.5 million for reaching $25 million in annual sales within two years of closing;

ii. a payment of $5 million for reaching $50 million in annual sales within three years of closing;

iii. a payment of $7.5 million for reaching $75 million in annual sales within four years of the closing; and

iv. a one percent (1%) annual royalty on sales for an additional four years after the $75 million sales amount is reached.

(ECF No. 60.1, at ¶ 32.)

7. Between October 2014 and May 2015, PRA was, again, given

unfettered access to test and analyze the Software Solutions and had ready access to

Parthasarathy and other VHS programmers to address questions about the Software

Solutions. PRA had the opportunity to verify all information provided by VHS and

1 The copy of the LOI, attached to the original Complaint, is not signed by VHS, and Plaintiffs

do not allege that Plaintiffs agreed to the LOI. Parthasarathy regarding the Software Solutions. PRA also had the opportunity to

analyze whether VHS’s Software Solutions had the ability to handle the scale and

scope of PRA’s intended use for the software. (Id. at ¶¶ 36–39.)

8. Effective May 21, 2015, PRA, VHS, and Parthasarathy entered into an

Asset Purchase Agreement (“APA”) for the purchase of the Software Solutions. (Id.

at ¶ 40; ECF No. 5, at Ex. B.) Under the APA, PRA agreed to purchase the Software

Solutions in exchange for a fixed payment at closing, and fixed and variable milestone

payments to be made after closing, as follows:

Fixed payment at closing:

(a) Shares of PRA stock valued at $1,957,000.00 (see APA, §2.5(b)(i)), plus a payment of $500,000, at closing (see APA, § 2.5(b)(ii));

Fixed payments for software milestones:

(b) Shares of PRA stock valued at $333,000 for each of the agreed-upon “Milestones”:

(i) “integration of the Parties’ Salesforce environments,” as set forth on Schedule 2.6(a)(i) of the APA, within 18 months of closing ([see] APA, § 2.6(a)(i));

(ii) “completion of the key product enhancements” as set forth on Schedule 2.6(a)(ii) of the APA (see APA, §2.6(a)(ii)) within 18 months of closing;

(iii) “completion of the migration of the clinical trial management systems studies” of PRA “into ClinTrial Max” as set forth on Schedule 2.6(a)(iii) of the APA (see APA, § 2.6(a)(iii));

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
2020 NCBC 41, Counsel Stack Legal Research, https://law.counselstack.com/opinion/value-health-sols-inc-v-pharm-research-assocs-ncbizct-2020.